Nicotine therapeutic benefits: Difference between revisions

Line 1,288:

='''Sarcoidosis'''=

===2021 [https://journal.chestnet.org/article/S0012-3692(21)01282-4/fulltext Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis]===

===2021 [https://journal.chestnet.org/article/S0012-3692(21)00962-4/fulltext A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis]===

*Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.

**Citation: A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis, Crouser, Elliott D. et al. CHEST, Volume 160, Issue 4, 1340 - 1349

===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]===

*The immune phenotype of patients with symptomatic [[wikipedia:Sarcoidosis|'''sarcoidosis''']] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population.

@@ Line 1,288: / Line 1,288: @@
 ='''Sarcoidosis'''=
 ===2021 [https://journal.chestnet.org/article/S0012-3692(21)01282-4/fulltext Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis]===
 ===2021 [https://journal.chestnet.org/article/S0012-3692(21)00962-4/fulltext A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis]===
+*Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.
+**Citation: A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis, Crouser, Elliott D. et al. CHEST, Volume 160, Issue 4, 1340 - 1349
 ===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]===
 *The immune phenotype of patients with symptomatic [[wikipedia:Sarcoidosis|'''sarcoidosis''']] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population.